- Home
- BHAT vs KZIA Comparison
BHAT vs KZIA Comparison
Compare BHAT & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BHAT
- KZIA
- Stock Information
- Founded
- BHAT 2010
- KZIA 1994
- Country
- BHAT China
- KZIA Australia
- Employees
- BHAT N/A
- KZIA N/A
- Industry
- BHAT Recreational Games/Products/Toys
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- BHAT Consumer Discretionary
- KZIA Health Care
- Exchange
- BHAT Nasdaq
- KZIA Nasdaq
- Market Cap
- BHAT 12.3M
- KZIA 9.0M
- IPO Year
- BHAT 2019
- KZIA 1999
- Fundamental
- Price
- BHAT $1.68
- KZIA $7.85
- Analyst Decision
- BHAT
- KZIA Strong Buy
- Analyst Count
- BHAT 0
- KZIA 2
- Target Price
- BHAT N/A
- KZIA $14.00
- AVG Volume (30 Days)
- BHAT 1.1M
- KZIA 137.3K
- Earning Date
- BHAT 04-30-2025
- KZIA 11-14-2025
- Dividend Yield
- BHAT N/A
- KZIA N/A
- EPS Growth
- BHAT N/A
- KZIA N/A
- EPS
- BHAT N/A
- KZIA N/A
- Revenue
- BHAT $18,724,190.00
- KZIA $1,549,158.00
- Revenue This Year
- BHAT N/A
- KZIA N/A
- Revenue Next Year
- BHAT N/A
- KZIA $49.25
- P/E Ratio
- BHAT N/A
- KZIA N/A
- Revenue Growth
- BHAT N/A
- KZIA 248983.08
- 52 Week Low
- BHAT $1.51
- KZIA $2.86
- 52 Week High
- BHAT $45.00
- KZIA $39.05
- Technical
- Relative Strength Index (RSI)
- BHAT 47.24
- KZIA 46.88
- Support Level
- BHAT $1.65
- KZIA $7.60
- Resistance Level
- BHAT $1.83
- KZIA $8.28
- Average True Range (ATR)
- BHAT 0.16
- KZIA 0.50
- MACD
- BHAT 0.00
- KZIA 0.02
- Stochastic Oscillator
- BHAT 20.32
- KZIA 24.26
About BHAT Blue Hat Interactive Entertainment Technology
Blue Hat Interactive Entertainment Technology is focused on commodity trading, including chemicals, jewelry, and precious metals such as gold. It operates a gold and diamond trading and supply chain business. Its business model encompasses physical gold trading, diamond trading, gold derivatives trading, and the development of AI-enabled trading platforms. Its segments include Diamond trading, Commodity trading, Information service, Interactive toys - animation series, and Interactive toys - game series. It derives revenue from Diamond trading. The majority of its revenues are generated in PRC.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.